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ABSTRACT
Objective: To elaborate recommendations of the Rheumatoid Arthritis Committee of the Brazilian Society of  Rheumatology 
(SBR) to manage comorbidities in rheumatoid arthritis (RA). Methods: To review the literature and the opinions of the 
SBR RA Committee experts. Results and conclusions: Recommendations: 1) Early diagnosis and proper treatment of 
comorbidities are recommended; 2) The specifi c treatment of RA should be adapted to the presence of comorbidities; 
3) Angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers are preferred to treat systemic arterial 
hypertension; 4) In patients diagnosed with rheumatoid arthritis and diabetes mellitus, the continuous use of a high cumu-
lative dose of corticoids should be avoided; 5) Statins should be used to maintain LDL cholesterol levels under 100 mg/dL 
and the atherosclerotic index lower than 3.5 in patients with RA who have other comorbidities; 6) Metabolic syndrome 
should be treated; 7) Performing non-invasive tests to investigate subclinical atherosclerosis is recommended; 8) Greater 
surveillance for the early diagnosis of occult malignancy is recommended; 9) Preventive measures of venous thrombosis 
are suggested; 10) Bone densitometry is recommended in RA patients over the age of 50 years and in younger patients 
on corticoid therapy at a dose greater than 7.5 mg for over three months; 11) Patients with RA and osteoporosis should be 
instructed to avoid falls, to increase their dietary calcium intake and sun exposure, and to exercise; 12) Calcium and vitamin 
D supplementation is suggested. Bisphosphonates are suggested for patients with T score < –2.5 on bone densitometry; 
13) A multidisciplinary team, with the active participation of a rheumatologist, is recommended to treat comorbidities.
Keywords: rheumatoid arthritis, comorbidities, arterial hypertension, diabetes mellitus, dyslipidemia.
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune infl am-
matory disease whose major characteristic is the presence 
of symmetric chronic polyarthritis of large and small joints. 
Despite its typical musculoskeletal involvement, RA is a 
systemic disease that may affect several organs, such as the 
lungs, eyes, and blood vessels. The condition causes a large 
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social and economic impact, considering the irreversible 
joint deformities and the signifi cant decline in the patients’ 
functional capacity.1 
In recent years, greater knowledge about the pathogenesis 
of RA and the recognition of therapeutic targets have allowed 
the use of the new disease-modifying antirheumatic drugs 
(DMARDs), including the biological DMARDs.2,3 In addition, 
new RA management strategies have been suggested, such 
as the use of DMARDs since the initial phase of the disease, 
more frequent assessments of patients, therapeutic changes or 
adjustments based on objective scores for assessing disease 
activity; and search for clinical remission or, when that is not 
possible, for low disease activity. Those management changes 
have resulted in improved prognosis for patients diagnosed 
with RA.4 
Despite the noticeable advances in the treatment of RA, 
mortality among patients with RA continues higher than that 
of the general population, with no signifi cant changes in recent 
years.5
Individuals diagnosed with RA have greater likelihood 
of having other diseases associated, such as those of autoim-
mune etiology,6,7 and comorbidities, such as systemic arterial 
hypertension (SAH), dyslipidemia, and diabetes mellitus 
(DM).8–14 The understanding and adequate management 
of the comorbidities of patients with RA are fundamental, 
because those diseases contribute to an increased cardio-
vascular risk and to the greater mortality observed in that 
group.15
The present study aimed at elaborating recommendations 
for the diagnosis and management of comorbidities in patients 
with RA, emphasizing the most frequent conditions. The pur-
pose of this document is to synthesize the current position of the 
Brazilian Society of Rheumatology (SBR) on the topic, aiming 
at instructing the Brazilian physicians, especially rheumatolo-
gists, about the diagnosis and management of comorbidities 
in patients with RA in Brazil. 
METHOD OF ELABORATING THE 
RECOMMENDATIONS
The method of elaborating the recommendations includes a 
literature review and the opinion of expert members of the 
Rheumatoid Arthritis Committee of the SBR. The bibliographic 
research comprised publications of MEDLINE, SciELO, 
PubMed, and EMBASE databases up to February 2012. The 
recommendations were written and reassessed by all partici-
pants during multiple rounds of questionings and corrections 
conducted on the Internet. 
Systemic arterial hypertension 
Systemic arterial hypertension is one of the major modifi able 
risk factors for cardiovascular disease in patients with RA. It 
is an important and frequent pathology, associated with the 
development of subclinical atherosclerosis. Its prevalence is 
high, ranging from 53%–73%, according to some published 
studies.14–16 Panoulas et al.14 have found a 70.5% frequency of 
hypertensives in their sample, while Gonzalez et al.16 have re-
ported a 52% frequency in the population studied. Despite that 
high frequency, SAH in RA has been less often diagnosed and 
treated (13.2% vs. 21%–23% in the population without RA).14–16 
The mechanisms responsible for the appearance of SAH 
in patients with RA have not been clarifi ed, but some classic 
factors, such as obesity, sedentary lifestyle, and use of medica-
tions, are associated with SAH in that population.15 The use 
of glucocorticoids for more than six months at a dose higher 
than 7.5 mg/day is associated with SAH in patients with RA.17 
Similarly, an increase in blood pressure levels secondary to the 
use of lefl unomide and cyclosporine can occur in patients with 
RA.18–20 Factors inherent to the disease, such as the systemic 
infl ammation of RA, might also contribute to the appearance 
of SAH in those patients. During its course, RA shows an 
increased expression of tumor necrosis factor alpha (TNF-α), 
interleukins (IL) 1 and 6, adhesion molecules, angiotensin II 
type 1 receptor, and endothelin, and a lower expression of nitric 
oxide; that unbalance might contribute to SAH.15
Regarding the treatment of RA, the use of non-steroidal 
anti-inflammatory drugs (NSAIDs) is known to attenuate 
the anti-hypertensive effect of diuretics, beta-blockers, angio-
tensin-converting enzyme inhibitors (ACEIs), and angiotensin 
II receptor blockers (ARBs).21 It is also worth noting that com-
bining NSAIDs with diuretics and ACEIs or ARBs increases 
the likelihood of renal failure, especially in elderly patients or 
in those with conditions losing intravascular volume, such as 
liver cirrhosis, heart failure, hypoalbuminemia, and dehydra-
tion. Due to their benefi cial effects at the endothelial level, and 
because they interfere less with the metabolism of carbohydrates 
and cause less dyslipidemia, ACEI and ARB, rather than beta-
blockers and diuretics, are preferred to initiate the treatment of 
SAH in patients with RA.15 In the treatment of patients with RA 
and SAH, whenever possible, the concomitant use of NSAIDs and/
or high doses of corticoids should be avoided.22
Diabetes mellitus
The association between RA and insulin resistance has been 
well documented. However, there are few studies assessing 
the risk of patients with RA developing DM.12,23,24 A recent 
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study comparing 48,718 patients with RA, 40,346 patients with 
psoriasis or psoriatic arthritis, and 44,2033 controls has shown 
that patients with RA were at higher risk of developing type 2 
DM as compared with controls (HR = 1.5; 95% CI 1.4–1.5).23
Similarly, Han et al.25 have shown that cardiovascular 
diseases and their risk factors, as well as type 2 DM, were 
more common among patients with RA. The use of corticoids 
in patients with RA is known to interfere negatively with 
the insulin sensitivity of patients with RA.26 In addition, the 
treatment of the systemic infl ammation of RA is known to be 
benefi cial, especially with the use of hydroxychloroquine and 
anti-TNF.27–29
Some studies have also shown that the prevalence of type 
1 DM is higher in patients with RA, especially in the subgroup 
positive for the anti-cyclic citrullinated peptide (anti-CCP) 
antibody. That risk can be attributed to an allele shared by both 
diseases, acting like a common risk factor in the pathogenesis 
of both diseases. Liao et al.,30 assessing 1,419 patients with RA, 
have shown that the presence of the PTPN22 allele is common 
to both RA and type 1 DM, relating to the coexistence of both 
diseases. However, the association was signifi cant only for 
patients with RA positive for the anti-CCP antibody. 
The continuous use of a high cumulative dose of corticoids 
to patients with concomitant RA and DM should be avoided, 
and strategies should be implemented for an effective control 
of the disease’s systemic infl ammation, considering that there 
is evidence suggesting a benefi cial effect of the RA treatment 
on DM control.27–29 
Dyslipidemia
The dyslipidemia found in patients with RA is characterized 
by the presence of reduced levels of HDL-cholesterol (HDL) 
and an increased total cholesterol/HDL ratio (TC/HDL).31–34 
The emergence of that pattern can precede the onset of RA 
articular manifestations and can be related to infl ammatory 
changes secondary to the disease.33,34
The levels of TC, and especially of HDL, are believed to 
decrease with disease activity, and that reduction might be 
related to the high levels of pro-infl ammatory cytokines, such 
as TNF-α.31,33 
The treatment of RA itself is known to be able to interfere 
with the patients’ lipid profi le.35–38 The NSAIDs do not seem 
to affect lipid levels.39 The effect of corticoids on the increase 
of TC and LDL levels have been widely documented, although 
their use in patients with RA has not been associated, so far, 
with increased cardiovascular risk.40 Cyclosporine seems to 
have a deleterious effect on cholesterol levels, while antima-
larials have a positive effect on reducing the serum levels of 
TC and triglycerides.41 Treatment with other DMARDs and 
biologics, such as the drugs of the anti-TNF class, and mainly 
with the IL-6 receptor inhibitor (tocilizumab) have controlled 
infl ammation and increased the previously reduced HDL and 
TC associated with infl ammation, without interfering with 
the atherosclerotic index (TC/HDL), and without increasing 
clinical cardiovascular events so far.42–45 
It is worth noting that the use of statin group drugs has not 
only lipid lowering effects on patients with RA, but reduces 
the disease activity scores. The result of the ongoing Trial of 
Atorvastatin for the Primary Prevention of Cardiovascular 
Events in Rheumatoid Arthritis (TRACE RA) (http://www.
dgoh.nhs.uk/tracera), which will involve 4,000 patients with 
RA, is awaited. That study will be able to defi ne the role of 
statins in controlling infl ammation and reducing the cardio-
vascular risk in patients with RA.46
Atherosclerosis
Patients with RA have a higher prevalence of endothelial 
dysfunction,47,48 assessed by brachial ultrasound imaging, be-
ing that the fi rst evidence of the beginning of the atherogenic 
process, in which arterial stiffness is found. Regarding the 
non-invasive tests that demonstrate the presence of subclinical 
atherosclerosis, studies have confi rmed that carotid atheroscle-
rosis with plaques is frequent,49 as well as a higher coronary 
artery calcium score on computed tomographic angiography.50
The prevalences of acute myocardial infarction (AMI) 
and congestive heart failure (CHF) are higher in patients with 
RA.51,52 Such conditions reduce survival and increase mortality 
of patients with RA. Regarding coronary artery disease, it is 
worth noting that angina symptoms are less frequent in patients 
with RA, and thus, those individuals often die suddenly or have 
silent myocardial infarction.51
Although the treatment of RA reduces the chance of 
myocardial infarction, especially with the use of methotrex-
ate (MTX) and anti-TNF,53–55 it is worth noting that treating 
comorbidities, such as type 2 DM, dyslipidemia and SAH, in 
such patients is important. 
In patients with RA, who have coronary artery disease, 
previous AMI or CHF, the indiscriminate and long-term use 
of NSAIDs, especially cyclooxygenase-2 selective NSAIDs, 
should be avoided, considering the greater mortality and 
the risk of hospitalization due to myocardial infarction and 
decompensated CHF. Of the NSAIDs, the risk of myocardial 
infarction, and other cardiovascular events seems to be lower 
with the use of naproxen.56,57
Another aspect to be considered is smoking cessation 
in patients with RA. In addition to increasing the risk of 
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cardiovascular disease, smoking is known to increase the 
chances of genetically predisposed individuals developing 
RA, to increase the severity of articular manifestations, and 
to be associated with extra-articular manifestations of the dis-
ease.58 Furthermore, smokers with RA have a lower clinical 
response to antirheumatic drugs, such as MTX, or to anti-TNF 
biologics.59
Metabolic syndrome
Although there is no universally accepted defi nition, metabolic 
syndrome (MS) is characterized by the clustering of clinical 
manifestations that include central obesity, reduced levels of 
HDL, high levels of triglycerides, increased blood pressure 
and hyperglycemia. Currently, the most accepted defi nitions 
are those issued by the International Diabetes Federation 
(IDF), the National Cholesterol Education Program – Adult 
Treatment Panel III (NCEP ATPIII), and the World Health 
Organization (WHO).60–62 
That syndrome represents an association of conditions 
having in common insulin resistance and increased abdominal 
fat, which are closely related to infl ammation.63 That relation 
to infl ammation can justify the higher prevalence of MS in 
patients with RA,9,64–67 and the higher disease activity found in 
patients with RA who also have MS.66–68 Dessein et al.69 have 
shown a 14%–19% prevalence of MS among patients with RA, 
and two other studies have not shown a greater prevalence of 
MS among patients with RA.68,70 The presence of MS in the 
population without RA has been associated with a greater 
chance of cardiovascular events and higher overall mortality.71 
There were no studies assessing the higher prevalence 
of myocardial infarction or stroke associated with MS in the 
population with RA,72 but the presence of coronary artery 
calcifi cation, which can be diagnosed in a test and increases 
the likelihood of a cardiovascular event, has been associated 
with MS in that population.65 The role of the DMARDs in the 
prevalence of MS in patients with RA has not been defi ned, 
with disagreeing results regarding MTX. Toms et al.73 have re-
ported a lower prevalence of MS in elderly patients using MTX; 
on the other hand, a subanalysis of the CARRE Investigation 
has not confi rmed those fi ndings.13
Venous thrombosis and pulmonary embolism
Deep venous thrombosis (DVT) and pulmonary thromboembo-
lism (PTE) stand out among noncardiac vascular events most 
likely to occur in RA.74,75 The incidence of those comorbidities 
can be associated with classic risk factors that affect the general 
population and with specifi c aspects of RA.74–76
In general, the following fi ndings contribute to increase 
the risk of thromboembolism: lower mobility consequent to 
joint lesions; hospitalizations with prolonged bed confi nement; 
more advanced age of most arthritic patients; compression of 
the venous system adjacent to a joint with huge joint effusion; 
and obesity.74 
Patients with RA have changes in the coagulation pa-
rameters and in the fi brinolytic system,77 the most common 
fi ndings being as follows: increased platelet count; increased 
platelet activation markers; and increased thrombin markers, 
such as thrombin-antithrombin complexes and prothrombin 
fragments. The increase in pro-infl ammatory cytokines in RA 
is associated with high levels of fi brinogen, von Willebrand 
factor, and D-dimer.77,78 
Although the studies on the prevalence of DVT and PTE 
in RA have shown discordant results, an important study 
has reported that RA is a risk factor for DVT and PTE.75,79,80 
That study has assessed the incidence of DVT and PTE in 
patients with RA hospitalized in the United States from 1979 to 
2005. The results were as follows: 41,000 of 4,818,000 (0.85%) 
patients with RA had PTE, as compared with 3,366,000 of 
891,055,000 (0.38%) patients without RA (RR = 2.25). Deep 
venous thrombosis occurred in 79,000 of 4,818,000 (1.64%) 
patients with RA as compared with 681,000 of 891,055,000 
(0.86%) patients without RA (RR = 1.90). Regarding the impact 
of the different treatments used for RA, data from the British 
Society for Rheumatology Biologics Register have compared 
the incidence of DVT and PTE in 11,881 patients on anti-TNF 
and 3,673 on nonbiological DMARDs. Overall, no difference 
was observed in the incidence of DVT and PTE in the different 
groups (HR = 0.8; 95% CI: 0.5–1.5).81
A retrospective population-based study has compared data 
from 813 patients with RA with those of individuals without 
RA, cared for from January 1980 to December 2007. The au-
thors have concluded that the incidence of DVT and PTE was 
greater in individuals with RA (HR = 3.6).74 Thromboembolic 
events were associated with obesity (HR = 2.2), use of 
DMARDs (except for MTX and hydroxychloroquine) 
(HR = 1.9), use of biologics (HR = 2.7), use of acetylsalicylic 
acid (HR = 2.3), and recent arthroplasty (HR = 11.4). However, 
they were not associated with venous thromboembolism, 
positivity for the rheumatoid factor and the anti-CCP antibody, 
increased erythrocyte sedimentation rate, severity of RA, and 
presence of erosions or subcutaneous nodules.
Thus, there is discordance between the North-American 
study and the British Society for Rheumatology Biologics 
Register, in which no association of PTE/DVT and immuno-
biologics has been found.74,81
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The recommendations for the care of patients with RA 
should include preventive measures against PTE/DVT. 
Malignancies
The occurrence of malignancies in patients with RA, either us-
ing DMARDs, especially biologics, or not, is of great interest, 
because of the great impact of those diseases on morbidity and 
mortality of patients with RA.
The results of studies of prevalence and relative risk as 
compared with a control population, and the role of the treat-
ment of RA (including synthetic and biological DMARDs) in 
triggering malignancies are still controversial.82–88 Population 
studies for data collection from primary sources are required 
to widen the knowledge on the mechanisms of malignancy 
occurrence in patients with RA.
The mortality risk due to specifi c causes in hospitalized 
patients with RA has been quantifi ed in a study based on a 
population cohort followed up for 20 years.89 Among patients 
with RA, the risk of death increased due to the causes listed 
in all chapters of the International Classifi cation of Diseases 
(ICD), except for the mental diseases. Specifi c causes of 
death in that group of patients included lung cancer [men: 1.4 
(1.2–1.5); women: 1.6 (1.5–1.8)] and hematopoietic malignan-
cies [men: 1.8 (1.4–2.3); women: 2.0 (1.7–2.3)]. Patients with 
RA, however, were less likely to die due to gastrointestinal tract 
malignancies [men: 0.82 (0.7–1.0); women: 0.8 (0.7–0.9)]. 
Hemminki et al.90 have also reported a reduction in the risk 
of colon and rectal adenocarcinomas in patients with RA, sug-
gesting that the underlying infl ammatory mechanisms acting 
as risk factors in those patients could have been suppressed 
by the use of anti-infl ammatory drugs.
The associated risk of four specifi c malignancies (lym-
phoma, and lung, colorectal and breast cancers) in patients with 
RA has been assessed in a meta-analysis.82 When compared 
with the general population, the standardized incidence ratio 
(SIR) estimates suggested that patients with RA had a two-
fold increase in lymphoma risk (SIR 2.08; 95% CI 1.80–2.39) 
and a greater risk of Hodgkin than non-Hodgkin lymphoma. 
The risk of lung cancer was also increased (SIR 1.63; 95% CI 
1.43–1.87). In contrast, a decrease in risk was observed for 
colorectal (SIR 0.77; 95% CI 0.65–0.9) and breast cancer (SIR 
0.84; 95% CI 0.79–0.9). The SIR for all malignancies was 1.05 
(95% CI 1.01–1.09). Thus, patients with RA seem to have a 
higher risk of lymphoma and lung cancer, and potentially lower 
risk of breast and colorectal cancer as compared with that of 
the general population.
Another study has followed 42,262 patients with RA up 
(with previous hospitalization) from 1980 to 2004 in Sweden. 
SIR has been calculated for malignancies in patients with 
RA as compared with that of individuals without RA. Many 
malignancies, such as Hodgkin and non-Hodgkin lymphomas, 
skin cancer, and endocrine tumors (except for thyroid), have 
been more often diagnosed in patients with RA. Tumors of the 
colon, rectum and endometrium were decreased in patients 
with RA. Among patients hospitalized after 1999, SIRs for 
melanoma, squamous cell carcinoma, upper digestive tract 
cancer and leukemia were increased as compared with those 
of the previous periods.84
The risk of the occurrence of non-Hodgkin lymphoma 
in patients with autoimmune diseases has been investigated in 
several studies and the results have been inconclusive. 
In a meta-analysis of cohort studies,83 a greater risk of non-
Hodgkin lymphoma has been reported in patients with RA 
(SIR 3.9; 95% CI 2.5–5.9). The random effects SIRs of 
non-Hodgkin lymphoma in patients with RA treated with 
synthetic DMARDs, cytotoxic drugs and biologics were 
2.5 (95% CI 0.7–9.0), 5.1 (95% CI 0.9–28.6), and 11.5 (95% CI 
3.7–26.9), respectively.
Data from the Swedish Early Arthritis Registry (symptom 
duration < 1 year) have shown that, before the diagnosis of RA, no 
increase in the risk of lymphoma (RR 0.67 [95% CI 0.37–1.23]) 
or other malignancies (RR 0.78 [95% CI 0.70–0.88]) was 
observed. Within the fi rst ten years after the diagnosis of 
RA, the HR for developing lymphomas was 1.75 (95% CI 
1.04–2.96). Those fi ndings indicate that, in general, the 
risk of lymphoma is increased in the fi rst decade after the 
diagnosis of RA.91
The pathogenesis of the occurrence of solid or hemato-
poietic malignancies in patients with RA is not known. The 
deregulation of the immune system in autoimmune diseases 
could lead to cancer, and there is defi nitive evidence relat-
ing some autoimmune mechanisms to the occurrence of 
malignancies.90
A signifi cant association of HLA-DRBI*02 and DRBI*03 
has been found with the likely occurrence of malignancies 
(OR 5.2 and 9.9, respectively), independently of the family 
history of RA and cancer or the clinical RA activity. Thus, 
HLA class II alleles seem to be associated with the occurrence 
of malignancies in patients with RA.92 
Despite the lack of previously published formal recom-
mendations, the Rheumatoid Arthritis Committee of the SBR 
recommends that, during the clinical follow-up of patients 
with RA, the clinician be permanently aware of any symptom 
that might suggest malignancy, because of its increased risk, 
especially in patients with severe forms and on biological 
DMARDs. The investigation for malignancies in patients with 
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RA should follow the same protocol of patients without RA, 
aiming at early diagnosis, and should include screening tests.
Biological DMARDs have been used for the treatment 
of RA for over one decade. Since then, the still incomplete 
understanding of their effects and of the inhibited pathways 
raises questions about the safety profi le of those drugs, includ-
ing the risk of cancer.88 
Regarding the anti-TNF agents, TNF is known to play an 
important role in infl ammation and can affect the control of 
tumor growth.89
The information available so far has not allowed stating 
precisely the most common types of tumors, the patients on 
biological DMARDs at risk for developing cancer, and the time 
of the possible occurrence of the tumor. Data that can be analyzed 
originate from meta-analyses of randomized controlled studies 
and observational studies, including the registries of biologics.89
 Data from the German Biologics Register RABBIT, a 
prospective cohort study, were used to investigate the risk of 
new or recurring malignancies in patients with RA on biologics 
as compared with other synthetic DMARDs. No signifi cant 
differences were found in the incidence of malignancies in 
patients exposed or not to treatment with anti-TNF and anti-
IL1. The same applies to the risk of recurring malignancies. 
The authors have suggested, however, that the results require 
being validated in larger cohorts.93
A recent systematic literature review87 has included all 
randomized, double-blind, placebo-controlled studies as-
sessing patients with initial RA who began anti-TNF therapy 
without the previous use of DMARD (including MTX), in a 
total of 2,183 patients on biologic therapy and 1,236 patients 
on MTX. No signifi cant difference regarding the occurrence of 
malignancies was observed between patients on anti-TNF and 
controls. The authors have concluded that the risk of malignan-
cies seems not to be increased in patients early diagnosed and 
not receiving previous treatment with MTX or other DMARD.
The safety of anti-TNF in patients with RA has also been 
assessed by calculating the estimated risk in meta-analyses 
with and without adjustment to exposure.94 Eighteen random-
ized studies involving 8,808 patients with RA have been 
included (mean treatment time of 0.8 year). The treatment 
with the recommended doses of anti-TNF has not increased 
the risk of death (RR 1.39; 95% CI 0.74–2.62), of lymphoma 
(RR 1.26; 95% CI 0.52–3.06), of non-melanoma skin cancer 
(RR 1.27; 95% CI 0.67–2.42), or the compound endpoint 
of non-cutaneous malignancies plus melanomas (RR 1.31; 
95% CI 0.69–2.48). 
In a meta-analysis comprising studies that had included 
patients with RA using etanercept (ETP) for at least 12 
weeks,95 3,316 patients have been assessed, of whom 2,244 
received ETP (2,484 person-years of follow-up) and 1,072, 
control therapy (1,051 person-years). Malignancies have been 
diagnosed in 26 patients in the ETP group [incidence rate (IR) 
10.47/1,000 person-years] and in seven patients in the con-
trol group (IR 6.66/1,000 person-years). The HR was 1.84 
(95% CI 0.79–4.28) for the ETP group as compared with the 
control group. In that analysis, the occurrence of malignancies 
was greater in patients treated with ETP, although the results 
were not statistically signifi cant.
To determine the short-term and medium-term malignancy 
risks in patients with RA and using anti-TNF, data from the 
following entities have been assessed and crossed: the Swedish 
Biologics Register (ARTIS); the Swedish registers of RA; and 
the Swedish Cancer Register. In the fi rst six years of anti-TNF 
therapy, no elevation in the malignancy risk has been observed.96
Another aspect to consider is the occurrence of cancer in 
patients with RA and previous history of malignancy treated 
with anti-TNF. Data from the British Society for Rheumatology 
Biologics Register have evidenced 293 patients with previous 
diagnosis of malignancies in a total of 14,000 patients with RA. 
The malignancy IRs were compared in 177 patients with RA 
treated with anti-TNF and 117 patients treated with synthetic 
DMARDs, all of whom had a previous diagnosis of malig-
nancy. The malignancy IRs were 25.3 events/1,000 person-
years in the anti-TNF cohort and 28.3/1,000 person-years in 
the synthetic DMARD cohort, generating an IR adjusted for 
age and gender of 0.58 (95% CI 0.23–1.43) for the cohort 
treated with anti-TNF as compared with the cohort treated 
with DMARDs. The authors have concluded that the way 
British rheumatologists select patients with RA and previous 
malignancies for biological therapy does not increase the oc-
currence of malignancies.97 Those data, however, should not be 
interpreted as indicative of the safety of the anti-TNF therapy 
for patients with RA and previous malignancies.
The 2008 edition of the WHO Classifi cation of Tumors 
of Hematopoietic and Lymphoid tissues recognizes a new 
diagnostic entity termed “other iatrogenic immunodefi ciency-
associated lymphoproliferative disorders”, highlighting lym-
phomas arising in patients treated with immunosuppressive 
agents for autoimmune disorders.98 
The role of anti-TNF therapy and lymphoma risk in patients 
with RA remains unclear. Wong et al.98 have published a meta-
analysis of all randomized controlled clinical trials describing 
patients diagnosed with RA receiving anti-TNF therapy. The 
adjusted overall rates were 0.36 lymphoma per 1,000 person-
years in patients who did not receive anti-TNF therapy vs. 1.65 
lymphomas per 1,000 person-years in patients who received 
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anti-TNF therapy. The corresponding 95% CI for that rate di-
fference was (–0.214, 2.79). The adjusted rate difference was 
1.29 lymphomas per 1,000 person-years (95% CI 0.21–2.3; 
P = 0.093). Thus, there is a suggestion of increased lymphomas 
in the group treated with anti-TNF, with the predominant subset 
being B-cell lymphomas. Since the occurrence of lymphoma 
is a rare event, there was no statistical signifi cance.
In another meta-analysis performed aiming at assessing the 
risk of malignancies in patients with RA treated with anti-TNF 
in clinical practice (prospective observational studies), the esti-
mated risk for tumors in all sites was 0.95 (95% CI 0.85–1.05).99 
In patients previously diagnosed with malignancies, a higher 
risk of tumor recurrence or of new diagnoses of malignancy was 
observed. That risk was not increased by exposure to anti-TNF. 
Results of four studies in that meta-analysis have suggested that 
patients treated with anti-TNF would have a signifi cantly higher 
risk of developing non-melanoma skin cancer (1.45, 95% CI 
1.15–1.76). In addition, patients had a higher risk of developing 
melanoma, the pooled estimate being 1.79 (95% CI 0.92–2.67). 
The pooled estimate for the risk of lymphoma was 1.11 
(95% CI 0.70–1.51). That systematic review has shown that 
anti-TNF therapies do not increase the risk of malignancies, 
particularly of lymphoma. However, that class of drugs seems 
to increase the risk of skin cancer, including melanoma.
Using data from the ARTIS, the Swedish Cancer Register, 
pre-existing RA cohorts and cross-linkage with other national 
health and census registers, a Swedish RA cohort (n = 67,743) 
was assembled and patients who began anti-TNF therapy be-
tween 1998 and July 2006 (n = 6,604) were identifi ed. A general 
population comparator (n = 471,024) was also assembled, the 
incidence of lymphomas from 1999 to 2006 being assessed and 
compared in those individuals. Of the 6,604 patients with RA 
treated with anti-TNF, 26 malignant lymphomas were observed 
during 26,981 person-years of follow-up, corresponding to a 
RR of 1.35 (95% CI 0.82–2.11) vs. anti-TN-naive patients 
with RA (336 lymphomas during 365,026 person-years) and 
RR of 2.72 (95% CI 1.82–4.08) vs. the general population 
comparator (1,568 lymphomas during 3,355,849 person-years). 
Patients with RA beginning anti-TNF therapy in 1998-2001 
accounted for the entire increase in lymphoma risk vs. the two 
comparators. However, RR has not signifi cantly varied with 
time since the beginning of the fi rst treatment or with the ac-
cumulated duration of treatment, or with the type of anti-TNF 
agent. In conclusion, as used in the routine care against RA, 
the anti-TNF agents are not associated with any major further 
increase in the already elevated lymphoma occurrence in RA. 
Changes in the selection of patients for treatment may infl u-
ence the observed risk.100
Data on the role of biological DMARDs other than anti-
TNF agents in the occurrence of malignancies in patients with 
RA are scarcer.
To obtain information on the occurrence of malignancies 
in patients with RA being treated with abatacept (ABT), data 
from the ABT clinical development program were compared 
with those of other patients with RA and of the general popu-
lation. A total of 4,134 patients with RA treated with ABT 
in seven different trials and 41,529 patients with RA treated 
with synthetic DMARDs in fi ve observational cohorts were 
included in the study. In the ABT-treated patients, the 51 
malignancies, excluding non-melanoma skin cancer and 
including seven cases of breast cancer, two cases of colorectal 
cancer, 13 cases of lung cancer, and fi ve cases of lymphoma 
observed were not greater than the range of cases found in 
the fi ve observational cohorts. The SIR comparing patients with 
RA with the general population was consistent with that reported 
in the literature. In conclusion, the IR of total malignancy (breast, 
colorectal and lung cancers and lymphoma) in the ABT clinical de-
velopment program was consistent with that of a population with 
RA not using ABT, although data require further monitoring.101
To determine the real-life conditions of safety of treatment 
with rituximab (RTX) in patients with RA regarding malig-
nancies, analysis of safety data from a cohort of patients with 
RA who received at least one course of RTX was performed. 
Patients with RA and previously diagnosed with malignancies 
were followed up and compared with the group of patients with 
no history of malignancy. The study selected 186 patients with 
RA. The mean follow-up was 22.3 ± 15 months, correspond-
ing to a follow-up of 346 patient-years of RTX exposure, of 
whom, 24 patients (12.9%) had a history of malignancy. Five 
cancers were diagnosed during follow-up as follows: four 
new malignancies (one prostate, one breast, one colon and 
one cervical cancer) and one recurrence of breast cancer. The 
overall malignancy rate was 1.45/100 patient-years (95% CI 
0.19–2.70), comparable to those of the previously studied 
DMARD-treated cohorts. No new hematopoietic malignancy 
was reported, and the six cases of lymphoma that had been in 
remission prior to RTX therapy remained under follow-up. 
Thus, although based on a small number of malignancy cases 
observed, and despite selection bias (12.9% of prior malig-
nancies in RXT-treated patients), that observational study has 
suggested that RTX does not increase the risk of malignancies 
in patients with RA.102
Up to 70% of the cancer diagnoses were made by non-
oncologist physicians, evidencing the importance of those 
professionals in disease control. Because RA is a condition 
associated with the occurrence of malignancies per se or 
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resulting from its treatment, rheumatologists should be aware 
of suspected symptoms. It is worth noting that constant 
surveillance is the only way to obtain proper diagnostic and 
therapeutic managements, and promptness in diagnosing and 
conducting the case is the only way to assure a reduction in 
morbidity and mortality due to malignancies.
Osteoporosis
Osteoporosis and fractures are common comorbidities in pa-
tients with RA, being part of the natural course of the disease. 
Although osteoporosis in RA has been extensively studied for 
the past years, it has been rarely addressed in clinical guide-
lines, its management often being given less attention in the 
care of arthritic patients. The relevance of this issue is refl ected 
in the high prevalence of those comorbidities, which can affect 
more than half of the patients with RA.103 Consequently, the 
risk of fractures is greater than that of the general population. 
In a retrospective study with more than 30,000 patients with 
RA, the risk of hip and spine fractures was approximately twice 
that observed in the general population, and almost three times 
greater in patients on glucocorticoids.104 In addition, almost 
20% of female patients with RA can have new fractures in 
fi ve years.105
The pathogenesis of RA explains the imbalance between 
bone production and resorption. The disease has an increased 
production of cytokines, such as IL-1, IL-6, TNF-α, and trans-
forming growth factor-beta, which stimulate infl ammation 
and are involved in osteoclast activation and differentiation.106 
Those cytokines regulate the expression of the receptor activator 
of nuclear factor kappa-β ligand (RANKL), and, consequently, 
osteoprotegerin (OPG), which are major mediators of bone re-
modeling.107 In addition to the RANK-RANKL-OPG pathway, 
Th17 lymphocytes seem to play an important role in bone re-
sorption through the selective production of pro-infl ammatory 
cytokines. Evidence suggests that Th17 lymphocytes have 
osteoclastogenic effects on murine models and accelerate bone 
loss in infl ammatory diseases.107,108
Rheumatoid arthritis is an independent risk factor for bone 
fracture.109 In the management of patients with RA, traditional 
risk factors, such as advanced age, history of previous fracture, 
corticotherapy, family history of hip fracture, low body weight, 
smoking, and alcohol abuse, should be assessed. Other clinical 
conditions that cause bone mass loss, such as hypogonadism, 
early menopause, and infl ammatory bowel disease, should 
also be documented in the clinical assessment. The character-
istics of the disease related to low bone mineral density are as 
follows: elevated HAQ (Health Assessment Questionnaire); 
functional classes III and IV; long-term disease; high activity 
scores; elevated infl ammatory tests; and corticotherapy.110 They 
should be identifi ed and minimized. Another independent risk 
factor for bone mass loss is sedentary lifestyle. Beginning 
physical activity can also reduce the risk of osteopenia and 
bone mass loss.111–113
Brazilian guidelines for assessment, prevention and treat-
ment of osteoporosis in patients with RA are urgently needed. 
In the initial assessment, bone densitometry should be indi-
cated for all patients over the age of 50 years. Bone mineral 
density should also be evaluated in patients under 50 years 
with an additional risk factor, such as history of fracture and 
corticotherapy (dose ≥ 7.5 mg of prednisone/day for more than 
three months).113 In patients with established osteoporosis, 
the following should be assessed: alkaline phosphatase; TSH; 
protein electrophoresis; and serum vitamin D. Regarding the 
non-pharmacological management, the following measures 
should be taken for all patients: to practice impact exercises; 
to prevent falls; to stop smoking; to increase sun exposure; 
and to avoid alcohol abuse. Special attention should be paid 
to patients on corticotherapy, in addition to calcium prescrip-
tion (1,200–1,500 mg/day) and vitamin D supplementation.114 
Regarding the pharmacological management, treatment with 
bisphosphonates should be preferentially indicated for all 
patients with a T score < –2.5 on bone densitometry, and for 
those on corticotherapy with a T score < –1.0.113,114
RECOMENDATIONS OF THE BRAZILIAN SOCIETY 
OF RHEUMATOLOGY FOR THE MANAGEMENT 
OF COMORBIDITIES IN PATIENTS DIAGNOSED 
WITH RHEUMATOID ARTHRITIS
Based on the previous considerations, the expert members of 
the Rheumatoid Arthritis Committee of the SBR have proposed 
the recommendations summarized in Table 1 for managing 
comorbidities in patients diagnosed with RA.
CONCLUSIONS
Recommendations for the early diagnosis and proper treatment 
of RA have been proposed in our consensus documents and are 
fundamental for improving the clinical outcomes of RA.115,116 
Similarly, understanding and managing comorbidities, such 
as osteoporosis, SAH, DM, dyslipidemia, MS, and athero-
sclerosis, are of great importance to reduce the disease-related 
morbidity and mortality and improve the patients’ quality of 
life. Being aware of the signs and symptoms that might sug-
gest the presence of malignancy at an initial phase is important 
to improve the prognosis of comorbidities. Pharmacological 
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and non-pharmacological measures to prevent venous throm-
bosis should be taken for patients with RA, considering their 
increased risk for that complication. 
Table 1
Recommendations of the Brazilian Society of Rheumatology for the management of comorbidities in patients diagnosed with 
rheumatoid arthritis
Recommendation 1: The early diagnosis and proper treatment of comorbidities, such as systemic arterial hypertension, diabetes mellitus, dyslipidemia, 
metabolic syndrome, and atherosclerosis are of great importance in the management of patients with rheumatoid arthritis, because they reduce disease-
related morbidity and mortality and improve the patients’ quality of life.
Recommendation 2: The specifi c treatment of rheumatoid arthritis should be adapted to the presence of comorbidities, using, whenever possible, drugs 
that control comorbidities. 
Recommendation 3: Because of the benefi cial effects on the endothelium, and because they interfere less with the metabolism of carbohydrates and 
cause less dyslipidemia, angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers are preferred to begin the treatment of systemic 
arterial hypertension in patients with rheumatoid arthritis, rather than beta-blockers and diuretics. In the treatment of patients with concomitant 
rheumatoid arthritis and systemic arterial hypertension, whenever possible, the continuous and joint use of anti-infl ammatory agents and/or high doses 
of glucocorticoid should be avoided.
Recommendation 4: In patients diagnosed with rheumatoid arthritis and diabetes mellitus, the continuous use of a high cumulative dose of corticoids 
should be avoided. Strategies for an effective control of the systemic infl ammation of rheumatoid arthritis should be implemented, because this seems to 
help control diabetes mellitus.
Recommendation 5: The occurrence of dyslipidemia in rheumatoid arthritis increases the risk of cardiovascular morbidity and mortality. Appropriate 
treatment should start early. Statins should be used to maintain LDL cholesterol levels under 100 mg/dL and the atherosclerotic index lower than 3.5 in 
patients with rheumatoid arthritis who have other comorbidities that increase even further the risk for a cardiovascular event (such as systemic arterial 
hypertension, diabetes mellitus and/or dyslipidemia), and in those with evidence of subclinical atherosclerotic disease, such as the presence of atheroma 
plaques in the carotid arteries.
Recommendation 6: The presence of metabolic syndrome in the population without rheumatoid arthritis is associated with a higher likelihood of cardiovascular 
events and higher overall mortality. All the components of that condition, such as central obesity, reduced HDL cholesterol levels, high triglyceride levels, 
increased arterial blood pressure, and hyperglycemia, should be properly treated. 
Recommendation 7: Considering the high prevalence of atherosclerosis in rheumatoid arthritis, and its accelerated and silent course, non-invasive 
tests to investigate subclinical atherosclerosis are recommended in patients with rheumatoid arthritis and comorbidities. Ultrasound imaging of the 
carotid arteries of patients over the age of 50 years and with rheumatoid arthritis is suggested to measure the intima-media thickness and investigate 
atheroma plaques.
Recommendation 8: Greater surveillance of signs and symptoms that might indicate an early diagnosis of occult malignancy in patients with rheumatoid 
arthritis is recommended to the rheumatologist, considering the greater prevalence of solid malignancies and lymphoma.
Recommendation 9: Pharmacological and non-pharmacological preventive measures, such as the use of unfractionated or low-molecular-weight 
heparin, should be considered in hospitalized patients with rheumatoid arthritis, because thromboembolic complications are more frequent in 
those patients.
Recommendation 10: Bone densitometry is recommended in rheumatoid arthritis patients over the age of 50 years and in younger patients on corticoid 
therapy at a dose greater than 7.5 mg for over three months.
Recommendation 11: Patients with rheumatoid arthritis and osteoporosis should be instructed to avoid falls, to increase their dietary calcium intake and 
sun exposure, and to exercise. 
Recommendation 12: Calcium and vitamin D supplementation is suggested to patients with rheumatoid arthritis on corticoids for more than three months, 
or to those who have other concomitant risk factors for fractures. Bisphosphonates are suggested for patients with T score < –2.5 on bone densitometry, or 
< –1.0 in the presence of other risk factors for osteoporosis.
Recommendation 13: A multidisciplinary team, with the active participation of a rheumatologist, is recommended to treat the comorbidities of diffi cult 
control in patients with rheumatoid arthritis.
The multidisciplinary follow-up of patients with RA and 
comorbidities diffi cult to control is suggested to determine a 
better clinical response to those associated pathologies.
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